Check out an invited and peer reviewed editorial released online 12/9/24 in Future Microbiology. This article focuses on Endolytix’ drug development program to change the paradigm of how NTM infections are treated.  Endolytix approach is patient focused, designed for targeted drug delivery to infected host cells, and is made of all natural ingredients in attempt to limit unwanted toxicities that are one of the largest problems facing NTM treatments. Written by our CSO, Dr. Jason Holder and collaborator Dr. Richard Slayden at Colorado State University. We put together the Endolytix drug development approach within context of current therapeutic options.